EU Filings For Orphan Status On The Decline
£12m In Fee Reductions For Rare Disease Drugs In 2019
Requests from sponsors for orphan drug status in the EU are showing a downward trend. It is not yet clear why, but a forthcoming report from the European Commission may provide some answers.
You may also be interested in...
Spring 2020 should see the publication of a working document by the European Commission on how to improve the operation of the EU legislation on orphan and pediatric medicines. The commission has asked for more input from member state experts.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.